Citigroup initiates coverage of Dutch Bros Inc. with a Buy rating and an $82 price target, citing the drive-through coffee chain's successful national scaling and multiple drivers for sustained same-store sales growth over the coming years.
A sustained plunge in the U.S. dollar's value, driven by soaring debt and geopolitical estrangement, threatens higher consumer costs, rising borrowing rates, and a sharp decline in foreign investment, economists warn.
A relentless focus on dividend yield may have led retirees and income investors to overlook one of the market's top performers. The Invesco NASDAQ 100 ETF (QQQM), with its scant 0.51% yield, has delivered over 108% total returns since inception by betting on growth, not income—a stark lesson in opportunity cost.
Lake Street Capital maintains a Buy rating on The ONE Group Hospitality (STKS) despite lowering its price target, citing a solid finish in a tough market and a clear growth runway through 2026.
JPMorgan raises its price target for Celsius Holdings (CELH) to $77, citing upside potential from its deepening PepsiCo partnership and the expanding distribution of its Alani Nu brand ahead of Q4 earnings.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
Baird raises its price target on Autoliv (ALV), citing resilience in the automotive safety giant's long-term outlook, even as near-term affordability concerns pressure the broader vehicle market.
Goldman Sachs and Baird reaffirm positive ratings on automotive technology supplier Visteon (VC), seeing significant upside potential even after modestly lowering price targets, driven by favorable sector outlook and growth in digital cockpit solutions.
As Bob Iger steps aside, incoming CEO Josh D'Amaro inherits a media giant facing stagnant growth, a challenged streaming division, and intense sector consolidation. Analysts debate whether a strategic overhaul or a potential sale offers the best path forward for the House of Mouse.
Target Corporation promotes Chief Operating Officer Michael Fiddelke to CEO, a move seen by many analysts as doubling down on the existing leadership team despite years of underperformance relative to rivals and the broader market.
The business intelligence firm, led by Michael Saylor, continued its Bitcoin acquisition strategy with a modest $75.3 million purchase last week, bringing its total holdings to 713,502 BTC. Despite a recent price correction, the company's average purchase price remains below current market levels.
Former UK ambassador to Washington, Peter Mandelson, faces intensifying political and public pressure to relinquish his lifetime seat in the House of Lords following new revelations about his financial and personal ties to the late convicted sex offender Jeffrey Epstein. Prime Minister Keir Starmer has called for his resignation, as documents suggest payments and close correspondence between the two.
A suspected human smuggler with a prior conviction was shot by federal agents near the Arizona-Mexico border after allegedly firing at a CBP helicopter and agents during a foot pursuit, according to law enforcement officials.
A federal appeals court has dismissed a Justice Department misconduct complaint against U.S. District Judge James Boasberg, ruling the government failed to substantiate its allegations regarding the judge's public comments.
Garrett Motion (GTX) is drawing strong buy ratings from analysts, with a median price target suggesting over 20% upside, driven by its strategic pivot to zero-emission vehicle technologies and resilient financial profile.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Analysts maintain a bullish outlook on Goodyear Tire & Rubber, citing strong potential in the replacement tire market and favorable inventory trends, with a median price target suggesting a 7% upside.
Aptiv PLC sees mixed but upwardly revised price targets from major analysts, with Piper Sandler upgrading the auto tech supplier to Overweight and naming it a top pick for 2026, citing its pragmatic strategy and attractive valuation.
